Monotherapy as adjunct to diet & exercise to improve glycemic control in type 2 DM. In combination w/ metformin, sulfonylureas, peroxisome proliferator-activated receptor (PPAR) agonist (eg, thiazolidinediones), rapid insulin secretagogues, α-glucosidase inhibitors, Na glucose co-transporter 2 inhibitor, or insulin to improve glycemic control in type 2 DM when the single agent alone, w/ diet & exercise, does not provide adequate glycemic control.
View Tenelia overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food.
Contraindications
History of hypersensitivity. Severe ketosis, diabetic coma or precoma, type 1 DM. Severe infection, pre- or post-op patients, & patients w/ serious traumatic injury.
Patients w/ cardiac failure (NYHA class III or IV); current or history of arrhythmia (eg, severe bradycardia), cardiac disease (eg, CHF), & hypokalaemia as they are prone to QT interval prolongation; history of abdominal operation or intestinal obstruction. Avoid in patients w/ current or history of QT interval prolongation (congenital long QT syndrome) or Torsades de Pointes. Concomitant use w/ sulfonylurea or insulin. Hypoglycaemia may occur in patients w/ pituitary or adrenal insufficiency; malnutrition, starvation, irregular diet, insufficient food intake or hyposthenia; extreme muscle exercise; excessive alcohol intake. Regularly monitor blood glucose & check drug effect during treatment. Acute pancreatitis. Severe hepatic impairment. May impair ability to drive & use machines caused by hypoglycemic symptoms. Pregnancy. Discontinue breastfeeding during treatment. Low-birth wt infants, neonate, nursing infants or childn. Elderly.
Sign Out
